Project Grant R01CA282467
Award Date
7/17/24
Completion Date
6/30/29
Dollars Obligated
$1.4M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $177,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The funding supports research to investigate the role of the NLRC4 inflammasome and caspase-8 activation in the pathogenesis of fibrolamellar carcinoma (FLC), a rare and aggressive form of liver cancer. The researchers will use mouse liver organoids engineered with the DNAJB1-PRKACA...
This $431,968 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Baylor College of Medicine to elucidate how the oncogene MYCN rewires the metabolic environment of neuroblastoma tumors to drive immune suppression, and to modulate this metabolic environment to enhance immune-based approaches for high-risk MYCN-amplified neuroblastoma. The research aims to uncover how MYCN amplification, a driver of aggressive neuroblastoma,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Hawaii at Manoa provides $402,400.00 to conduct research aimed at targeting neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) for immunotherapy of hepatoblastoma, the most common primary liver cancer in children. The 2-year grant period runs from May 15, 2025 to April 30, 2027. The key objectives are to determine which oncogenes drive PMN-MDSC recruitment in a...
The National Cancer Institute (NCI) awarded a 5-year, $678,515 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The University of Texas MD Anderson Cancer Center to evaluate the use of 18F-FSPG PET imaging and liquid biopsy (circulating tumor DNA) to predict response and detect recurrence in hepatocellular carcinoma (liver cancer) patients treated with yttrium-90 radioembolization therapy. The project aims to determine if 18F-FSPG PET can identify treatment-resistant...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $225,101.00 to Baylor College of Medicine to conduct research on how the oncogene MYCN drives an immune-suppressive tumor microenvironment in neuroblastoma. The goal is to delineate the molecular mechanisms through which MYCN reprograms T cell metabolism to impair T cell effector functions and create a suppressive tumor immune environment. This 2-year project aims to (1) determine how...
The National Cancer Institute (CFDA 93.395 Cancer Treatment Research) awarded a $267,298 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research aimed at targeting the CDK4/6 pathway in MIT/TFE-translocation renal cell carcinoma (TRCC), an aggressive and underserved form of kidney cancer. The research project will use genetic and pharmacologic approaches to test the sensitivity of TRCC cells to CDK4/6 inhibition, both alone and in combination with PI3K/mTOR pathway...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research (CFDA 93.395) grant program, awarded a $456,414 Project Grant to Seattle Children's Hospital to conduct a Phase 2 clinical trial of B7-H3 chimeric antigen receptor (CAR) T-cell therapy for children and young adults with diffuse intrinsic pontine glioma (DIPG), a fatal central nervous system tumor. The key products and services to be delivered under this grant include: Opening a Phase 2 clinical trial (BrainChild-05)...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...